Web Analytics

3 Latest Announced Rounds

  • $3,500,000
    Seed

    1 Investors

    Technology, Information and Internet
    Dec 20th, 2024
  • $5,619,170
    Series B

    1 Investors

    Research Services
    Dec 20th, 2024
  • $8,000,000
    Unknown

    5 Investors

    Computer & Network Security
    Dec 20th, 2024
$671.88M Raised in 44 Funding Rounds in the past 7 Days - View All

Funding Round Profile

CardioMech AS

start up
Norway - Trondheim
  • 03/01/2024
  • Unknown
  • $13,000,000

Mitral Regurgitation is the third most common cardiovascular disease that occurs when there is backward flow of blood across the mitral valve. It is highly prevalent, debilitating for patients, and deadly if untreated. The market is expected to be larger than the TAVR market, currently a $6B market.

The CardioMech device is an artificial chord that is designed to reduce or eliminate regurgitation and to restore the native anatomy. This catheter-based therapy is intended to be a simple and straightforward procedure and an alternative therapy option for both patients eligible for open-heart surgery and those considered surgically ineligible. Therefore, the CardioMech device can potentially reduce the need for open-heart surgery and may lessen the need for watchful waiting in younger and healthier patients.

Caution: Investigational device. Limited by law to investigational use.


Related People

Jacob BergslandCo Founder

Jacob Bergsland Norway - Oslo, Oslo

With over 30 years of experience as a cardiac surgeon and a doctor, I am currently the Chief Medical Officer at CardioMech AS, a medical device company developing a novel transcatheter mitral valve repair technology. I hold an MD and a PhD in medicine and cardiac surgery from the University of Oslo, and I have multiple certifications and publications in the field. My specialty education in General and Cardiothoracic Surgery was in Buffalo NY, where I subsequently practiced Cardiac Surgery at Buffalo VAMC and at Kaleida Health. My core competencies include medical education, healthcare management, clinical research, and innovation. I am passionate about improving the quality of life and outcomes for patients with heart diseases, and I am dedicated to advancing the field of cardiac surgery through cutting-edge technology and collaboration. As the CMO at CardioMech AS, working closely with our CEO Rick Nehm and the management team, I participate actively in the clinical development, regulatory affairs, and medical affairs of the company, and I work closely with the engineering, and business development teams to ensure the safety, efficacy, and value proposition of our products. I also partner with leading cardiologists, surgeons, and researchers around the world to conduct clinical trials, generate evidence, and disseminate knowledge. I bring diverse perspectives and experiences to the company, as I have worked in different countries and settings, such as Norway, Bosnia, in addition to more than 20 years in the US, and I speak multiple languages. I am always eager to learn new skills and explore new challenges, and I strive to contribute to the company's mission and vision.
I am dedicated to support of the free world and has worked part time in Bosnia and Herzegovina for almost 30 years as an educator and hospital developer. I am presently working on projects in Bosnia, Norway and the United States.